Therapeutic medications against diabetes: What we have and what we expect

被引:50
|
作者
Hu, Cheng [1 ,2 ]
Jia, Weiping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Shanghai Diabet Inst,Shanghai Key Lab Diabet Mell, 600 Yishan Rd, Shanghai 200233, Peoples R China
[2] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, South Campus,6600 Nanfeng Rd, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetes; Treatment; Drug delivery; Natural product; GLUCAGON-LIKE PEPTIDE-1; COTRANSPORTER; 2; INHIBITORS; ENCAPSULATES SUBCUTANEOUS IMPLANTS; INADEQUATE GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; BLOOD-GLUCOSE CONCENTRATION; GLP-1 RECEPTOR AGONISTS; BETA-CELL FUNCTION; ORAL DELIVERY; INSULIN DELIVERY;
D O I
10.1016/j.addr.2018.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related complications. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidiabetic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes control, with its greater efficiency, increased bioavailability, decreased toxicity and reduced dosing frequency. Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great potential in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. Our paper aim to overview these therapeutic methods for diabetes therapy. Proper combinations of these existing anti diabetic medications and searching for novel routes are both necessary for better diabetes control. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 50 条
  • [21] WHAT CAN WE EXPECT
    ROWLAND, AB
    AMERICAN JOURNAL OF NURSING, 1966, 66 (10) : 2175 - 2176
  • [22] What can we expect?
    Aires de Carvalho, Helder Buenos
    de Sousa, Jose Elielton
    PENSANDO-REVISTA DE FILOSOFIA, 2018, 9 (17): : 1 - 1
  • [23] Medications in the COBY study: What have we learned?
    Hafeman, Danella
    Rooks, Brian
    Merranko, John
    Liao, Fangzi
    Gill, Mary Kay
    Goldstein, Tina
    Diler, Rasim
    Goldstein, Benjamin
    Axelson, David
    Birmaher, Boris
    BIPOLAR DISORDERS, 2024, 26 : 21 - 21
  • [24] What have we said? What have we done?
    Lehmann, Jennifer
    Redshaw, Lorraine
    CHILDREN AUSTRALIA, 2005, 30 (03) : 4 - 9
  • [25] WHAT WE EXPECT AND WHAT ITS LIKE
    MOORE, P
    PSYCHOLOGY TODAY, 1975, 9 (03) : 29 - 30
  • [26] Erratum to: Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
    A. Torres
    P. Bonanni
    W. Hryniewicz
    M. Moutschen
    R. R. Reinert
    T. Welte
    European Journal of Clinical Microbiology & Infectious Diseases, 2015, 34 : 415 - 416
  • [27] The success of extragalactic infrared interferometry: from what we have learned to what to expect
    Tristram, Konrad R. W.
    Honig, Sebastian F.
    OPTICAL AND INFRARED INTERFEROMETRY AND IMAGING VI, 2018, 10701
  • [28] COVID-19 Pandemic: What Have We Learned and What to Expect in the Future?
    Freudenberg, Lutz S.
    Pomykala, Kelsey L.
    Herrmann, Ken
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (01) : 86 - 89
  • [29] Doing what we can with what we have
    Lowe, Eric G.
    Lowe, Kathryn M.
    ANNALS OF EMERGENCY MEDICINE, 2008, 51 (03) : 328 - 329
  • [30] What we have failed and what we are insisting on
    Gauss, Karl-Markus
    LITERATUR UND KRITIK, 2016, (509): : 3 - 4